Physician profile
Vincent Bett
NPI 1285320655
$2,021.62
in general payments reported to CMS, 2019-2025
16 companies · $1,574 in 2025
The $1,574 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $448 · 2025: $1,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,021.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $359.49 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $230.05 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $207.25 | 2024-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Lundbeck LLC | $183.61 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Abbvie INC. | $155.82 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $128.87 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $120.93 | 2024-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.25 | 2024-2025 | Caplyta |
| Tris Pharma INC | $104.97 | 2025 | Dyanavel Xr, Onyda Xr |
| Neurocrine Biosciences, INC. | $90.04 | 2025 | |
| Alkermes, INC. | $77.42 | 2024-2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $67.64 | 2025 | Cobenfy |
| Bausch Health US, LLC | $64.12 | 2024-2025 | Aplenzin |
| Biogen, INC. | $47.76 | 2024 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $39.77 | 2025 | Trintellix |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $28.63 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Bett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.